were approximately 24. This is very similar to previous studies of omadacycline against S. pneumoniae (stasis AUC/MIC 18) and other PK/PD evaluations of tetracycline-class antibiotics. 1-log kill targets were only 2-3 fold more than stasis targets for each strain. This data should provide useful in the dose-regimen optimization of omadacycline.
Conclusion. DLX 300 mg IV, q12hr, should achieve fAUC24/MIC ratios that are adequate to treat ABSSSI caused by most contemporary isolates of EC and PA. For EC, isolates with DLX MICs ≤0.25 μg/mL comprised 73% of all isolates. For PA, isolates with DLX MICs ≤1 μg/mL comprised 88% of all isolates. Similar results would be expected for TAP with oral DLX 450 mg, q12hr.
Disclosures. R. Hoover, Melinta Therapeutics: Consultant, Consulting fee; A. Marra, Melinta Therapeutics: Employee, Salary; E. Duffy, Melinta Therapeutics: Employee, Salary; S. K. Cammarata, Melinta Therapeutics: Employee, Salary Friday, October 6, 2017: 12:30 PM Background. Intra-abdominal candidiasis (IAC) is a prominent invasive fungal infection associated with high mortality. Prompt antifungal therapy and source control are crucial for successful treatment. Echinocandin antifungal drugs are first-line agents. Yet, their clinical effectiveness is highly variable with known potential for breakthrough resistance, and little is known about drug exposure at the site of infection. Using matrix-assisted desorption/ionization (MALDI) mass spectrometry imaging as well as standard analytical techniques, we investigated the spatial and quantitative distribution in tissue lesions for two echinocandin drugs, micafungin and CD101, in a clinically relevant IAC mouse model.
Unraveling Drug Penetration of Echinocandin
Methods. Female 6-8 week old CD1 mice weighing 18-22 g were infected intraperitoneally (IP) with 1 × 10 7 CFU of C. albicans SC5314 mixed with sterile stool matrix. Single IP doses of CD101 at 5 or 20 mg/kg (equivalent to humanized therapeutic dose) or micafungin at 5 mg/kg (therapeutic dose) were administered to mice at day 3 post-inoculation. Mice were sacrificed at just before antifungal treatment (n= 1), and at 1, 3, 6, 24, and 48 hours post-dose (n = 3 per group per time point). Liver and kidney lesions were collected for MALDI imaging. Laser capture microdissection (LCM) followed by liquid chromatography coupled tandem mass spectrometry (LC/ MS-MS) was applied to 6 and 24 hours samples for drug exposure measurement. In a separate experiment, mice were treated with 2 or 3 doses of micafungin (5 mg/kg), or a single dose of CD101 (20 mg/kg). Drug accumulation was analyzed at 48 and 72hours post the first dose.
Results. Drug accumulation within lesions was observed with both drugs at their humanized therapeutic dose. However, micafungin, even at steady-state, failed to approach the mutant prevention concentration (MPC) (16 µg/mL) of the infecting strain. CD101 demonstrated extensive penetration into the lesions after a single dose administration and persisted in lesions at above MPC level of 29.7 µg/mL at 72 hours postdose.
Conclusion. These findings indicate that current echinocandin drugs may be limited by penetration at the site of infection, which have implications for clinical outcomes and emergence of resistance in patients with IAC.
Disclosures Background. Multi-drug resistant superbugs are a serious health threat due to limited treatment options and high mortality rates. Certain superbug strains are now resistant to as many as 36 representative FDA-approved antibiotics, including Colistin and Carbapenem antibiotics, widely considered as the last line of defense against untreatable infections. Nitric oxide (NO) is a diatomic free radical employed by the immune system to eradicate bacteria via oxidative and nitrosative stress. To facilitate storage and controlled release of NO, we have developed NO donor-modified biopolymers based on chitosan, a linear polysaccharide composed of randomly distributed β--linked D-glucosamine and N-acetyl-D-glucosamine. Herein, we report the broad spectrum antibacterial action of low molecular weight (5 kDa) NO-releasing chitosan against Gram-positive and Gram-negative multi-drug-resistant bacterial species, including Klebsiella pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa.
Methods. MIC assays were performed using CLSI guidelines in a 96-well plate format. All assays were carried out in triplicate using a two-fold dilution range. The bacterial suspension was then diluted in assay medium to a target concentration of approximately 5 × 10 5 CFU/mL, after which it was added to all test and growth control wells, and allowed to incubate. Test wells were scored for the lowest NO concentration released from the chitosan to inhibit visual growth of the pathogen. After MIC determination, wells demonstrating inhibition were plated, incubated and resulting colonies counted to determine survival concentration. The lowest concentration of NO to inhibit ≥99.9 % of a given test organism was reported as the MBC. Of note, chitosan alone showed no antibacterial action.
Results. MIC and MBC assays for NO-releasing chitosan against six multi-drug resistant strains are provided below.
Conclusion.
The properties of the NO-releasing chitosan, including water solubility, make it an excellent drug candidate for treating respiratory infections. Such development is currently underway.
Disclosures. Friday, October 6, 2017: 12:30 PM Background. Kampo medicine mainly contain crude extracts of natural products such as plants, animals, and minerals that are prepared according to classical Kampo methodologies. Since plants synthesize numerous antimicrobial components such as plant defensins, Kampo medicine likely contain potent antimicrobial constituents. We have tested antifungal activity of 61 commercially available Kampo medicines by using micro-broth dilution assay with Trichophyton rubrum (T. rubrum), and found that 7 of them had antifungal activity. Among these 7 Kampo medicines 6 contained Ou-gon which derived from the roots of Scutellaria baicalensis Georgi, and a crude extract of Ou-gon exhibited significant antifungal activity. This study aims to identify antifungal components contained in Ou-gon, and determine their antifungal mechanism.
Methods. T. rubrum, T. mentagrophytes, Aspergillus fumigatus (A. fumigatus) and Candida albicans (C. albicans) were used for antifungal activity assay. The antifungal activity assay was performed by measuring 595 nm absorbance in micro-broth dilution assay. Active components were analyzed by high performance liquid chromatography (HPLC), and identified by liquid chromatography electrospray ionisation mass spectrometry (LC-ESI-MS/MS). TUNEL assay, SYTOX-Green Uptake analyses, intracellular reactive oxygen species accumulation assay, mitochondrial membrane potential assay, scanning electron microscopy, and transmission electron microscopy were used to clarify the antifungal mechanism of active components.
Results. Upon HPLC analysis, two low molecular weight-compounds were isolated having potent antifungal activity. The two compounds were identified as Baicalein and Wogonin by LC-ESI-MS/MS. Baicalein showed antifungal activity for T. rubrum, T. mentagrophytes, A. fumigatus and C. albicans. Wogonin showed antifungal activity for all except C. albicans. Detection of antifungal mechanism of Baicalein and Wogonin suggested that their mode of action is apoptosis-like programmed cell death.
Conclusion. Baicalein and Wogonin are major compounds to have antifungal activity in Kampo medicine. This study may contribute to the development of new and safe antifungal drugs, especially for the clinical treatment of pathogenic fungal infections.
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